DermEffects: Dr. Wei Jing Loo
1560 Hyde Park Road
London, ON N6H 5L5
(519) 472-8686 (Cosmetic Inquiries)
(519) 472-2929 (Medical Inquiries)
(519) 472-8484 (Fax)
Monday–Friday: 7 a.m.–3 p.m.

Research & Clinical Trials

Dr. Loo is an adjunct professor at the University of Western Ontario and is very familiar with the rigor needed to conduct research and clinical trials that produce valuable results.

Dr. Wei Jing Loo uses her expertise and extensive training to help advance the fields of medical and cosmetic dermatology through her London, Ontario, practice. Regulatory agencies such as Health Canada and the FDA in the United States require clinical research trials before approving new treatments, preventive procedures, or devices.

Dr. Loo is an adjunct professor at the University of Western Ontario and is very familiar with the rigor needed to conduct research and clinical trials that produce valuable results. She has published her work in many peer-reviewed journals and has presented her research at national and international meetings.

Dr. Loo is an adjunct professor at the University of Western Ontario and is very familiar with the rigor needed to conduct research and clinical trials that produce valuable results.

Dr. Loo and her staff follow strict protocols and regulations when conducting clinical research trials.

Patients interested in participating in a clinical trial, sometimes called clinical studies, can volunteer by contacting DermEffects. If you’re accepted to participate, you can also decide to withdraw at any time.

Other important information to know for patients who participate in clinical research trials include:

  • Your participation is voluntary.
  • All information about you remains confidential.
  • Before participating in a study, Dr. Loo or another member of the clinical research team will explain all the details about the study to patients, including any potential risks or benefits, and answer all questions.
  • Patients have as much time as necessary to decide if they want to participate.
  • Patients who decide to participate must sign a consent form. They will keep a copy of this consent form, which contains additional information about the clinical research trial.

An Elite Skincare Specialist

Dr. Loo is an experienced, board-certified dermatologist who established DermEffects with a vision of providing excellent cosmetic and medical skin care.

Meet Dr. Wei Jing Loo Request a Consultation

Every clinical research trial is submitted to an independent research ethics board for approval before the study can be performed.

If you’re interested in learning about current clinical research trials, please visit ResearchTrials.org.

Please note that a physician referral is required for all medical consultations and treatments. Medical consultations are a benefit of Ontario Health Insurance Plan (OHIP). Elective services offered at DermEffects are not covered by OHIP.

Active Clinical Trials

We are currently recruiting for the following studies:

Adolescent-Adult Atopic Dermatitis Research Trial (61 Weeks)

Adolescents and adults aged 12 years to75 years with a diagnosis of atopic dermatitis (AD), may qualify to participate. Individuals must have Moderate to Severe AD with involvement of 10% or more body surface area (BSA). A history of AD with at least 6 months history of inadequate response to topical AD medications, or have required systemic treatment  for control of disease

Participants will receive investigational topical medication (active study drug) or placebo, via a cream. Study medication and study-related care will be provided at no cost. Reimbursement for study-related expenses will also be provided.

Study participation will last about 8 weeks and involve about 5 visits to the study centre.

Adult Facial Vitiligo Research Trial (30 Weeks)

Adults aged 18 years or older with a diagnosis of Non-segmented Facial Vitiligo may qualify to participate. Individuals must have moderate to severe Vitiligo on their face, vitiligo in other areas of the body, is permitted. However, the areas to be treated in the study will only include the face, neck, hands, forearms, and elbows.  with involvement of > 0.25 to 15% body surface area (BSA).

Participants will receive investigational topical medication (active study drug) or placebo, via a cream in conjunction with phototherapy or placebo.

Study medication and study-related care will be provided at no cost. Reimbursement for study-related expenses will also be provided.

Hidradenitis Suppurativa Research Trial 2 (20 Weeks)

Adults aged 18 years or older with a diagnosis of hidradenitis suppurativa (HS) for at least 6 months, may qualify to participate. Individuals must have HS lesions present in at least 2 distinct areas of the body. Moderate to severe disease with at least 5 inflammatory nodules or abscesses, must be present. Inadequate response to a course of a systemic antibiotic for the treatment of HS, is also required.

Participants will receive investigational medication (active study drug) or placebo, orally. Investigational medication and study-related care will be provided at no cost. Reimbursement for study-related expenses will also be provided.

Prurigo Nodularis Research Trial (52 Weeks)

Adults (male or female) aged 18 years to 80 years  with a clinical diagnosis of prurigo nodularis (PN) for at least 6 months, may qualify to participate. Individuals must have nodular lesions on the upper limbs, trunk, and/or lower limbs with at least 20 nodules on the entire body, distributed bilaterally (on both sides). Moderate to severe disease must be present, as well as severe pruritus (itch).

Participants will receive investigational medication (active study drug) or placebo, via injection. At Week 16 everyone will be investigational medication (active study drug)

Investigational medication and study-related care will be provided at no cost. Reimbursement for study-related expenses may be provided.

Adult Plaque Psoriasis Research Trial (21 Weeks)

Adults aged 18 to 75 years old diagnosed with plaque psoriasis for at least 6 months, may qualify to participate. Individuals must have moderate to severe plaque psoriasis involving 10% or more body surface area (BSA). Avoidance of any prolonged exposure to natural or artificial sources of ultraviolet (UV) radiation (e.g. sunlight, tanning beds or phototherapy) is also required.

Participants will receive investigational medication (active study drug) or placebo in tablet formulation. Study medication and study-related care will be provided at no cost. Reimbursement for study-related expenses will also be provided.

Study participation will last about 21 weeks and involve about 7 visits to the study centre.

Comparator Trial for Plaque Psoriasis (68 Weeks)

Adults aged 18-75 years old with stable moderate to severe plaque psoriasis for at least 6 months, may qualify to participate. Individuals must have psoriatic involvement of 10% or more body surface area. Previous failure, inadequate response, intolerance, or contraindication to at least 1 conventional anti-psoriatic systemic therapy is required. There must also be no known history of latent or active tuberculosis (TB); testing will occur at screening.

Participants will be part of one of two groups: the continued-use group (receiving ustekinumab) OR the switching group (receiving investigational medication (active study drug) and ustekinumab), via subcutaneous injection. Study medication and study-related assessments will be provided at no cost. Reimbursement for study-related expenses will also be provided.

Study participation will last about 68 weeks and involve about 14 visits to the study centre.

Prurigo Nodularis Research Trial (20-28 Weeks)

Adults (male or female) aged 18 years or older with a clinical diagnosis of prurigo nodularis (PN) for at least 6 months, may qualify to participate. Individuals must have nodular lesions on the upper limbs, trunk, and/or lower limbs with at least 20 nodules on the entire body, distributed bilaterally (on both sides). Moderate to severe disease must be present, as well as severe pruritus (itch).

Participants will receive investigational medication (active study drug) or placebo, via injection. Investigational medication and study-related care will be provided at no cost. Reimbursement for study-related expenses may be provided.

At the end of the treatment period, individuals may be eligible to enter a long-term extension (LTE) study. As such, study participation could be 20 weeks and 6 visits to the study centre (if enter LTE) or 28 weeks and 7 visits to the study centre (for individuals who do not enter LTE).

Hidradenitis Suppurativa Research Trial 2 (71 Weeks)

Adults aged 18 years or older with a diagnosis of hidradenitis suppurativa (HS) for at least 6 months, may qualify to participate. Individuals must have HS lesions present in at least 2 distinct areas of the body. Moderate to severe disease with at least 5 inflammatory nodules or abscesses, must be present. Inadequate response to a course of a systemic antibiotic for the treatment of HS, is also required.

Participants will receive investigational medication (active study drug) or placebo, via injection. Investigational medication and study-related care will be provided at no cost. Reimbursement for study-related expenses will also be provided.

Study participation will last about 71 weeks and involve about 28 visits to the study centre.

Research Trial for Alopecia Areata (32 Weeks)

Adults aged 18-65 with a definitive diagnosis of alopecia areata with a current episode of scalp hair loss lasting at least 6 months (not exceeding 10 years), may qualify to participate. Total disease duration greater than 10 years is permitted. Individuals must have at least 50% scalp hair loss.

Participants will receive investigational oral medication (active study drug) or placebo. Investigational medication and study-related care will be provided at no cost. Reimbursement for study-related expenses may also be provided.

Study participation will last about 32 weeks and involve about 10 visits to the study centre.

Child-Adult Atopic Dermatitis Research Trial (8 Weeks)

Children and adults aged 6 years or older with a diagnosis of atopic dermatitis (AD), may qualify to participate. Individuals must have mild to moderate AD with involvement of 3% or more body surface area (BSA). A history of AD for at least 3 months (if 6-17 years of age) or 6 months (if 18+ years of age) is required along with stable disease for the past 4 weeks with no significant flares, before screening.

Participants will receive investigational topical medication (active study drug) or placebo, via a cream. Study medication and study-related care will be provided at no cost. Reimbursement for study-related expenses will also be provided.

Study participation will last about 8 weeks and involve about 5 visits to the study centre.

Plaque Psoriasis – 8 weeks

Individuals 12 years of age or older with a diagnosis of plaque psoriasis for at least 6 months, may qualify to participate. Eligible participants must have plaque psoriasis covering 2-20% of their body, not including scalp, palms or soles of the feet, with mild to moderate disease at the time of study entry.

Participants will receive investigational topical medication (active drug) or a placebo. Study medication and study-related care will be provided at no cost. Reimbursement for study-related expenses may be provided, along with an optional open label extension upon completion of the trial.

Study participation will last 8 weeks.

Email Tina Craig, Clinical Research Coordinator at DermEffects to register.

Hidradentitis Suppurativa – 71 weeks

Men and women ages 18 years or older with a diagnosis of hidradenitis suppurativa (HS) and disease lasting for at least 6 months, may qualify to participate in this study. Individuals must have moderate to severe hidradenitis suppurativa with 5 or more inflammatory lesions in at least 2 distinct areas. Must also have no prior use of Cosentyx, Siliq or Taltz, and an inadequate response to oral antibiotics.

Eligible participants will receive investigational injection medication (active drug or placebo). Study medication and study-related care will be provided at no cost. Reimbursement for study-related expenses may be provided.

Study participation will last up to 71 weeks and include about 29 visits to the study centre.

Email Tina Craig, Clinical Research Coordinator at DermEffects to register.

Observational Psoriasis Research Study

You may qualify if you take pills, injections, infusions, or are receiving light therapy for psoriasis. Participants must be 18 or older. If you qualify, you’ll have regular visits with psoriasis specialists. There is no cost to participate, and participants will receive reasonable compensation for travel or parking cost.

Participants will be asked to visit the study centre about 11 times over a 5 year period.

Email Tina Craig, Clincal Research Coordinator at DermEffects to register.